Hoberman Kenneth 4
4 · STEMLINE THERAPEUTICS INC · Filed Jun 10, 2020
Insider Transaction Report
Form 4
Hoberman Kenneth
Chief Operating Officer
Transactions
- Disposition from Tender
Common Stock
2020-06-10−1,374,352→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2020-06-10−44,058→ 0 totalExercise: $4.12Exp: 2026-02-24→ Common Stock (44,058 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-06-10−25,000→ 0 totalExercise: $5.77Exp: 2026-01-07→ Common Stock (25,000 underlying) - Award
Common Stock
2020-06-10+600,000→ 1,374,352 total
Footnotes (4)
- [F1]Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement").
- [F2]Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
- [F3]All options were vested and exercisable as of the effective time of the merger.
- [F4]Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.